Updates in Lung Cancer
|
|
- Melvin Barker
- 5 years ago
- Views:
Transcription
1 Updates in Lung Cancer J. Tanner Ringley, PharmD, BCOP, CPP Levine Cancer Institute Learning Objectives: Discuss incorporation of liquid biopsies into practice and interpretation of immunotherapy biomarker assays Evaluate selected trials responsible for new indications in immunotherapy based non-small cell lung cancer (NSCLC) treatment Outline new EGFR-mutant NSCLC treatment recommendations Assess changes in ALK(+)-NSCLC treatment selection Traditional Diagnostic Flow Initiated with multidisciplinary evaluation Patient risk assessment Biopsy timing often dictated by several factors: Tumor location Pt comorbidities Procedure risk Process doesn t fit all patients Tan, W. et al. Non Small Cell Lung Cancer Workup. Medscape 1
2 Diagnostics Reck, Martin et al. N Engl J Med. 2017;377: Liquid Biopsy Two types: -Circulating tumor cells -Plasma based nucleic acid fragments (ie cfdna, mirna, ctdna) Liquid Biopsy Tissue biopsies poses issues Obtaining adequate tissue, multiple procedures possible Patient access to surgical/ir services Results often take longer/ greater chance for delay Dependent on adequate amounts of circulating tumor cells or respective nucleic acid substrate Variable sensitivity and specificity Limited current options available Can be cost prohibitive Current place in therapy? Case by case basis for now Re-testing on progression Mack et al. J Thorac Oncl Suppl Arneth. BMC Cancer :527 2
3 PD-1/PD-L1 treatment: how hard can it be? Large inter-/intra- malignancy type variation in tumor microenvironment Intra-malignancy tissue subtypes Impact on response = next phase of research Opportunity for expertise Sznol, Mario et al. Clin Cancer Res (19)2: Image: PD-L1 Assays: Points to Consider Primary vs. Metastatic disease Tumor biopsy heterogeneity: multiple tumors, multiple passes within a tumor Biopsy type: FNA vs. core vs. excisional Time between biopsy and treatment: effect of therapies Definition of positive results Type of cells expressing PD-L1 Location of TILs relative to PD-L1 staining Staining intensity Distribution: Patchy vs. diffuse, tumoral vs peripheral Expression level can affect drug utilization (ie Pembrolizumab) Current state Common assays: 28-8 assay (Nivolumab), 22c3 assay (Pembrolizumab), SP142 assay (Atezolizumab), SP263 (Durvalumab), & E1L3N (Yale lab test) Providers/supporting staff often unaware of assay being utilized and/or the existence of multiple assays ASCO. Immuno-Oncology 2018 Update. Bramer, J.R. 3
4 90 NSCLC tissue sample examined by 13 pathologists Specifically developed a standard scoring protocol Results: 28-8(Nivo), 22c3(Pembro), and E1L3n showed concordance SP142(Atezo) significantly lower mean score for PD-L1 exp Implications: Assure practice is utilizing appropriate test 28-8(Nivo) & 22c3(Pembro) most commonly utilized Be cautious when interpreting assay results to direct tx choice Rimm, DL. et al. JAMA Oncol. 2017;3(8): Question 1 A patient presents to your clinic with newly diagnosed advanced NSCLC, and is found to not be a chemotherapy candidate. The MD initially prescribes Pembrolizumab and sends the patients biopsy for PD-L1 testing (using the 22c3 IHC assay). PD-L1 expression = 60%. The patient turns out to be a self-pay patient, and can luckily qualify for free Atezolizumab through their patient assistance program. What is your recommendation to the MD? A) The tissue was only tested for Pembrolizumab, and would need to be re-tested if selecting another drug. B)Atezolizumab is a viable option in this scenario, given the 22c3 assay showed sufficient expression C)Recommend re-testing with the SP142 assay for Atezolizumab D)Recommend comparative testing of all three assays PACIFIC trial:phase III, placebo-cont, (interim analysis) Pts: Stage III, locally advanced, unresectable, NSCLC, s/p chemo+radiation Durvalumab (anti-pd-l1) vs placebo for 12 month consolidation tx, post-chemo Co-primary endpoints: PFS & OS Secondary endpoints: 12 & 18 month PFS rate, ORR, DOR, time to death or distant metastases, and safety Atonia, S.J., et al. NEJM Nov 16;377(20):
5 PACIFIC study cont. 713 randomized 709 received treatment 2:1 randomization ( 473 durvalumab, 236 placebo) Durvalumab 10mg/kg IV q2wks x 12 months Results: PFS: 16.8 months vs 5.6 months 12 month PFS rate: 55.9% vs 33.8% 18 month PFS rate: 44.2% vs 27% Atonia, S.J., et al. NEJM Nov 16;377(20): PACIFIC study cont. ORR: 28.4% vs 16% DOR(@18 months): 72.8% vs 46.8% Time to death or distant metastases: 23.2 months vs 14.6 months Safety: Grade 3/4 AE rate: 29.9% vs 26.1% Discontinuation rate: 15.4% vs 9.8% Brain metastases development (5% vs 11%) Pneumonitis: 6.3% vs 4.3% (not sig) Benefit observed regardless of PD-L1 status, stage IIIa or IIIb, and histologic type Practice Implications: New standard of care Will likely shape design of future trials Rizvi, Naiyer. NEJM : Keynote 189: Double blind, placebo-controlled, Phase III study Pts: treatment naive, metastatic, non-squamous, without sensitizing mutations Pembro/Pem/Platinum vs Placebo/Pem/Platinum Q3wks x 4 cycles Followed by Pembro or Placebo q21 days up to 35 cycles Primary Endpoints: OS & PFS Secondary Endpoints: ORR, DOR, & Safety Ghandi, L. et al. NEJM ;378(22):
6 Keynote-189 cont. OS(12 month): 69.2% vs 49.4% (HR = 0.49) 51% reduction in death Last reported OS (Nov 2017): NR (Pembro) vs 11.3 mo (Placebo) Ghandi, L. et al. NEJM ;378(22): Keynote-189 cont. Improved OS seen across all PD-L1% groups OS benefit positive correlation with PD-L1% Ghandi, L. et al. NEJM ;378(22): Keynote-189 cont. Median PFS (12 month): 34.1% vs 17.3% (8.8 mo vs 4.9 mo) Median PFS benefit correlated with PD-L1% TPS>50% = 9.4 mo TPS<1% = 6.1 mo Ghandi, L. et al. NEJM ;378(22):
7 Keynote-189 cont. ORR: 47.6% vs 18.9% ORR correlated with PD-L1% TPS>50% ORR = 61.4% vs TPS<1% ORR = 32.3% Median DOR: 11.2 mo vs 7.8 mo Safety: Grade 3/4 AE rate: 67.2% vs 65.8% Acute kidney injury: 5.2% vs 0.5% Nephritis: 1.7% vs 0% Practice implications: Superior OS, irrespective of PD-L1% Addition of immune-related AEs New standard of care Ghandi, L. et al. NEJM ;378(22): Question 2 63yo male w/ newly diagnosed, unresectable, stage IIIa, NSCLC. Driver mutations tests returned negative, and the patient was not deemed a candidate for radiation therapy. The patient has controlled T2DM with stage II CKD as the only complication. What would be the most appropriate therapy? A) Paclitaxel 200mg/m2 + Carboplatin AUC=6 IV q21days x 4 cycles B) Paclitaxel 50mg/m2 + Carboplatin AUC=2 weekly x 6 cycles, followed by Durvalumab 10mg/kg IV q2wks x 12 months C) Cisplatin 75mg/m2 + Docetaxel 75mg/m2 q21days x 4 cycles D) Cisplatin 75mg/m2 + Pemetrexed 500mg/m2 IV q21 days x 4 cycles Checkmate 227: Open label, multipart, Phase 3 study Pts: Stage IV or recurrent NSCLC not previously treated with chemotherapy, w/ high tumor mutational burden Dual arm study: PD-L1>1% vs PD-L1<1% PD-L1>1% randomized 1:1:1 Nivo+Ipi/Nivo/Chemo PD-L1<1% randomized 1:1:1 Nivo+Ipi/Nivo+chemo/Chemo Stratified: Squamous vs Non-squamous Hellmann, MD. et al. NEJM May 31;378(22):
8 Hellmann, MD. et al. NEJM May 31;378(22): Tumor Mutational Burden Somatic mutation prevalence in tumor cell DNA Associated with accumulation of neo-antigens Increased immune system recognition of tumor cells Attracts tumor-infiltrating lymphocytes (TILs) Checkmate-026: Nivo failed to improve OS over chemo, 1 st line Subgroup analysis: Improved PFS in high TMB tumors Alexandrov, Ludmil et al. Nature August 22; 500(7463): Checkmate 227 cont. Co-primary endpoints: Ipi/Nivo vs chemo PFS (blinded-independent review) in population selected for TMB OS in population selected for PD-L1 expression status Secondary endpoints: PFS in Ipi/nivo vs. chemo in pts with high TMB & PD-L1>1% Exploratory endpoints: ORR, DOR, and safety Chemo selection: histological based platinum doublet Stable non-squamous: allowed to continue pemetrexed or pemetrexed/nivolumab maintenance No Crossover permitted Hellmann, MD. et al. NEJM May 31;378(22): Checkmate 227 cont. N=1739 pts, 1004 pts assessed for TMB, 444 pts high TMB No correlation seen between TMB level and PD-L1 status PFS in pts w/ low TMB: (not-sig. HR=1.07) Ipi/Nivo = 3.2 months Chemo = 5.5 months PFS in pts w/ high TMB: (sig. difference) Ipi/nivo = 7.2 months Chemo = 5.5 months 8
9 Checkmate 227 Final Thoughts Benefit not seen in low-tmb patients PFS was significantly better in the high-tmb subgroup Regardless of PD-L1 status and histological type Establishes TMB as possible response & outcome biomarker NNT ~ 4 to 5 patients in high TMB group Safety was not significantly different across groups Greater immune related AEs w/ Ipi/nivo Greater grade 3/4 events w/ chemo Are we ready for full immuno? diagnostics lacking Missed opportunity? - sequential chemo/immuno Hellmann, MD. et al. NEJM May 31;378(22): EGFR-TKI Landscape 1 st /2 nd gen EGFR-TKIs have been 1 st line standard T790M mutation detected in >50% EGFR(+)-NSCLC progression cases Osimertinib approved in 2015 for T790M(+) NSCLC Osimertinib up to 200x greater affinity for exon-19 del & T790M mutations 3 rd gen - decreased affinity for wild type EGFR Dong, Lijun, et al. Oncotarget (8) p FLAURA trial: Double blind, phase 3 study, interim analysis Pts: Untreated, EGFR-mutant (+), advanced, NSCLC Dual arm study: 1:1 randomization Osimertinib 80mg qd Standard EGFR-TKI (Erlotinib 150mg/Gefitinib 250mg) Primary endpoint: Investigator-assessed PFS Secondary endpoints: OS, ORR, DOR, disease control rate, depth of response, and safety Soria, JC, et al. NEJM Jan 11;378(2):
10 Soria, JC, et al. NEJM Jan 11;378(2): FLAURA trial cont. PFS and OS was significantly better with Osimertinib in all subgroups AEs grade 3 or higher: 34%(Osi) vs 45% (standard TKI) Standard EGFR-TKI adverse events occurred less w/ Osimertinib (ie rash, diarrhea, dry skin, stomatitis) No significant difference in rate of discontinuation, dose interruption, and/or dose reduction FLAURA trial cont. Duration of response: 17.2(Osi) vs 8.5 months Also showed slightly better initial tumor size reduction PFS in pts w/ CNS mets: 15.2(Osi) vs 9.6 months Osimertinib previously outperformed chemo in CNS metastatic NSCLC Greater BBB penetrance vs 1 st /2 nd gen EGFR-TKIs Clinical consensus: Osimertinib first line for all? No T790M, exhaust 1 st /2 nd gen choices first Tx after progression on Osimertinib? Osimertinib 1 st line, clonal selection for other mutations? Patient by patient basis: CNS mets vs early stage dx Soria, JC, et al. NEJM Jan 11;378(2): Question 3 72yo patient with Stage IV, metastatic NSCLC. Recent cranial imaging confirmed multiple brain metastases, and biomarker testing reveals an EGFR exon19 deletion (+), T790M mutation (-). The patient is otherwise healthy with no significant comorbidities. What is the most appropriate therapy choice? A) Start with erlotinib first line until disease progression and/or acquired resistance. B) Start with afatinib first line until disease progression and/or acquired resistance. C) Start with gefitinib first line until disease progression and/or acquired resistance. D) Start with osimertinib first line until disease progression and/or acquired resistance. 10
11 ALEX trial: randomized, open label, phase 3 study Pts: untreated, ALK-positive, advanced, NSCLC Dual arm study: randomized 1:1 Alectinib 600mg bid Crizotinib 250mg bid Primary endpoint: Investigator-assessed PFS Secondary endpoints: independent-review PFS, time to CNS progression, ORR, and OS Peters, S, et al. NEJM Aug 31;377(9): ALEX trial cont. Primary: PFS significantly improved median = 17.7 mo vs 11.1 mo OS trended in favor of alectinib HR 0.76, p=0.24 Benefit was consistent across all subgroups No significant difference in dose intensity Grade 3 or higher adverse events: 41%(Alect) vs 50%(Crizot) No significant difference in overall and serious adverse event rates across both groups Alectinib: Anemia, myalgia, elev t-bili, photosensitivity Crizotinib: Nausea, diarrhea, vomiting Peters, S, et al. NEJM Aug 31;377(9): ALEX trial cont. Time to CNS progression longer w. Alectinib (HR=0.16) CNS progression events: 18 pts(alect) vs 68 pts(crizot) ALK(+)-NSCLC increased rate of CNS mets at diagnosis and/or lifetime risk of CNS disease Alectinib high CNS penetrance not PGP substrate Implications: Alectinib 1 st line Improved outcomes regardless of CNS involvement Crizotinib still niche in ROS-1 ALK(+) niche very dynamic Peters, S, et al. NEJM Aug 31;377(9):
12 Question 4 Which of the following is true based on the results of the ALEX trial (alectinib vs crizotinib) in ALK(+) NSCLC? A)The CNS progression was significantly lower in the alectinib trial arm B) The primary endpoint investigated was overall survival C) Crizotinib showed a lower adverse event rate D) Progression free survival was not significantly different between the two treatment arms Pilot study Neoadjuvant Nivolumab in untreated, early stage(i, II, or IIIa), resectable NSCLC Primary endpoint: Safety and Feasibility Secondary endpoint: Pathological response, PD-L1% 21 pts rec d two treatments of Nivolumab 3mg/kg IV, 4 wks prior to surgery Low & acceptable side effect profile, no surgery delays Major pathological response in 9 pts (45%) and complete response in 3 pts Correlation between pre-treatment tumor mutational burden and pathological response Forde, P.M., et al. NEJM May 24;378(21): Forde, P.M., et al. NEJM May 24;378(21):
13 Forde, P.M., et al. NEJM May 24;378(21): ASCO Update: Keynote-042 Pembrolizumab vs platinum-based chemotherapy as first line treatment for advanced/metastatic NSCLC with PD- L1 TPS ( 1%) Primary endpoint: OS 1274 pts (637 per arm), PD-L1% groups of >50%, >20%, and > 1% Demonstrated superiority to chemo in OS improvement Lopes, G, et al. J Clin Oncol 36, 2018 (suppl; abstr LBA4). ASCO Update: Keynote-407 Pembrolizumab combined w/ Carboplatin + Paclitaxel/nab-Paclitaxel as first-line treatment for squamous NSCLC Primary Endpoint: OS Significantly improved OS vs chemo alone Risk of death decreased by 36% (HR = 0.64, p=0.0008) Benefit consistent across subgroups, regardless of PD-L1 expression Showed ORR improvement over chemo alone 58.4% vs 35% 5 th study showing improved survival benefit with Pembrolizumab in advanced NSCLC Paz-Ares, LG, et al. J Clin Oncol 36, 2018 (suppl; abstr 105). 13
14 Small Cell Lung Cancer: ROVA-T Rovalpituzumab tesirine DLL3 targeted antibody-drug conjugate DLL3 = biomarker found on approx. 80% of tumor initiating cells in small cell lung cancer Initial phase 1 study showed promising results Phase 2 (TRINITY) results released March, 2018 Investigate efficacy as 3 rd line option Failed to meet proposed ORR cutoff Abbvie not seeking accelerated approval Small cell lung cancer still lacking in research advancement Rudin, CM, et al. Lancet Oncol Jan;18(1):42-51 Tropomysin receptor kinase (TRK) fusion proteins found in many cancer types Primary endpoint: ORR Secondary endpoint: DOR, PFS, and safety 55 pts (ages 4 months to 74 yo) 17 unique TRK-fusion (+) tumor types (4 NSCLC) ORR = 75%, DOR = 71% at 1 year, 55% PFS at 1 year NSCLC pts showed large tumor reductions Median DOR and PFS not yet reached Most AEs grade 1, grade ¾ <5% Drilon, A, et al. NEJM Feb 22;378(8): Refrences Reck, Martin et al. Precision Diagnosis and Treatment of Non-Small Cell Lung Cancer.N Engl J Med 2017;377: Arneth, Borros. Update on the types and usage of liquid biopsies in the clinical setting: a systematic review. BMC Cancer :527. Mack, P et al. Clinical Utility of Circulating Tumor DNA (ctdna) Analysis by Digital next Generation Sequencing of over 5,000 Advanced NSCLC Patients. J Thorac Oncl Suppl : s Rizvi, Naiyer. Immunotherapy for Unresectable Stage III Non Small-Cell Lung Cancer. NEJM : Sznol, M. et al. Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer. Clin Cancer Res Mar 1; 19(5): ASCO. Immuno-Oncology 2018 Update. Bramer, J.R. Available at: Rimm, DL. et al. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non Small Cell Lung Cancer. JAMA Oncol. 2017;3(8): Atonia, S.J., et al. Durvalumab after Chemoradiotherapy in Stage III Non Small-Cell Lung Cancer. NEJM Nov 16;377(20): Rizvi, Naiyer. Immunotherapy for Unresectable Stage III Non Small-Cell Lung Cancer. NEJM : Ghandi, L. et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. NEJM ;378(22):
15 References Hellmann, MD. et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. NEJM May 31;378(22): Alexandrov, Ludmil et al. Signatures of mutational processes in human cancer. Nature August 22; 500(7463): Dong, Lijun, et al. Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients. Oncotarget (8) p Soria, JC, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non Small-Cell Lung Cancer. NEJM Jan 11;378(2): Peters, S, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non Small-Cell Lung Cancer NEJM Aug 31;377(9): Forde, P.M., et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. NEJM May 24;378(21): Lopes, G, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) 1%: Open-label, phase 3 KEYNOTE-042 study. Clin Oncol 36, 2018 (suppl; abstr LBA4). Paz-Ares, LG, et al. Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). J Clin Oncol 36, 2018 (suppl; abstr 105). Rudin, CM, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol Jan;18(1):42-51 Drilon, A, et al. Efficacy of Larotrectinib in TRK Fusion- Positive Cancers in Adults and Children. NEJM Feb 22;378(8):
Updates in Lung Cancer. J. Tanner Ringley, PharmD, BCOP, CPP Levine Cancer Institute
Updates in Lung Cancer J. Tanner Ringley, PharmD, BCOP, CPP Levine Cancer Institute Learning Objectives: Discuss incorporation of liquid biopsies into practice and interpretation of immunotherapy biomarker
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationRecent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO
Recent Advances in Lung Cancer: Updates from ASCO 2018 Updates from ESMO, AACR and ASCO Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationRecent Advances in Lung Cancer: Updates from ASCO 2017
Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationRecent Advances in Lung Cancer: Updates from ASCO 2016
Recent Advances in Lung Cancer: Updates from ASCO 2016 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/23/2016
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationREPORT ASCO 2018 CHICAGO: RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital KU Leuven and Leuven Lung Cancer Group
1 REPORT ASCO 2018 CHICAGO: RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital KU Leuven and Leuven Lung Cancer Group OUR 10 MESSAGE HIGHLIGHTS 1/ Advanced NSCLC 1 st line: IO
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More informationThe role of immune checkpoint inhibitors in non-small cell lung cancer
Review Article Page 1 of 9 The role of immune checkpoint inhibitors in non-small cell lung cancer Tiffany L. George 1, Erin M. Bertino 2 1 Divisions of Hematology and Medical Oncology, 2 Division of Medical
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationAlessandro Inno. IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Verona
GRUPPO C Coordinatore: Diego Signorelli Ruolo dei checkpoint inhibitors nelle neoplasie polmonari: le evidenze scientifiche e l inserimento dei checkpoint inhibitors nell algoritmo decisionale del NSCLC
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationESMO 2017 CONGRESS September 2017 Madrid, Spain. Developed in association with the European Thoracic Oncology Platform
Developed in association with the European Thoracic Oncology Platform ESMO 2017 CONGRESS Congress 8 12 September 2017 Madrid, Spain Supported by Eli Lilly and Company. Eli Lilly and Company has not influenced
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationTargeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont. Masterclass 27 september 2018
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont Masterclass 27 september 2018 Outline Introduction EGFR TKI ALK TKI TKI for uncommon driver mutations Take home messages The promise of
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationNon-Small Cell Lung Cancer:
Non-Small Cell Lung Cancer: Where We Are Today Sila Shalhoub, PharmD PGY2 Oncology Pharmacy Resident Shalhoub.Sila@mayo.edu Pharmacy Grand Rounds September 26, 2017 2017 MFMER slide-1 Objectives Identify
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationImmunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationLung Cancer Update 2016 BAONS Oncology Care Update
Lung Cancer Update 2016 BAONS Oncology Care Update Matthew Gubens, MD, MS Assistant Professor Chair, Thoracic Oncology Site Committee UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Consulting
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationThe Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance
The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance H. Jack West, MD Swedish Cancer Institute Seattle, WA GRACE Targeted Therapies Forum September 16, 2017 Cleveland, OH EGFR Mutation-Positive
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationTargeted Therapy for NSCLC: EGFR and ALK Fadlo R. Khuri, MD
EGFR and ALK Fadlo R. Khuri, MD President, American University of Beirut Professor of Medicine July 26, 2018 A great year end! Targeted Therapy for NSCLC: Evolving Landscape of Lung Adenocarcinoma NSCLC
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More informationESMO 2018 CONGRESS October 2018 Munich, Germany. Developed in association with the European Thoracic Oncology Platform
Developed in association with the European Thoracic Oncology Platform ESMO 218 CONGRESS 19 23 October 218 Munich, Germany Supported by Eli Lilly and Company. Eli Lilly and Company has not influenced the
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationOptimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
More informationUnderstanding Options: When Should TKIs be Considered?
Advanced Stage Squamous NSCLC: Evolution and Increasing Complexity of the Therapeutic Landscape Understanding Options: When Should TKIs be Considered? David R. Gandara, MD University of California Davis
More informationAdvances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie
Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationOTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento
OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento Dolores Isla Servicio de Oncología Médica HCU Lozano Besa de Zaragoza 2008 Selection Factors in Advanced NSCLC ( 8y ago)
More informationSequencing in EGFR-Mutated NSCLC: Does Order Matter?
Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Pembrolizumab (Keytruda) for Nonsquamous Non-small Cell Lung Cancer April 4, 2019
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Pembrolizumab (Keytruda) for Nonsquamous Non-small Cell Lung Cancer April 4, 2019 DISCLAIMER Not a Substitute for Professional Advice
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationCURRENT STANDARD OF CARE OF LUNG CANCER. Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff
CURRENT STANDARD OF CARE OF LUNG CANCER Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff Biopsy: Establish Diagnosis, Determine Histologic Subtype,
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationDebate 1 Are treatments for small cell lung cancer getting better? No:
Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationEGFR Mutation-Positive Acquired Resistance: Dominance of T790M
Treatment of EGFR Mutation-Positive Acquired Resistance: T790M+ or T790M- H. Jack West, MD Swedish Cancer Institute, Seattle, WA EGFR Mutation-Positive Acquired Resistance: Dominance of T790M Yu, Clin
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationImmunotherapy in Non-Small Cell Lung Cancer
Immunotherapy in Non-Small Cell Lung Cancer Renato G. Martins Stephen H. Petersdorf Endowed Chair in Cancer Care Associate Medical Director, Solid Tumor Adult Oncology, Seattle Cancer Care Alliance Professor,
More informationADVANCES IN LUNG CANCER TREATMENTS
ADVANCES IN LUNG CANCER TREATMENTS Joan H. Schiller, MD Deputy Director of Clinical Research; Chief of Hematology/Oncology Inova Schar Cancer Institute; Fairfax, VA Chair of the Scientific Steering Committee,
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationNewest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management
Newest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management Stacey Jassey Megan Brafford David Kwasny This CE activity was originally presented live at the 2015 NASP Annual Meeting
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationO DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More information3/13/2018. Case 1. Multidisciplinary Management of Cancers Thoracic Oncology Tumor Board
Multidisciplinary Management of Cancers Thoracic Oncology Tumor Board Matthew Gubens, MD MS, UC San Francisco, Chair Julia Rotow, MD, UC San Francisco, Fellow Colin Blakely, MD PhD, UC San Francisco GigI
More informationCurrent Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationALK positive Lung Cancer. Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan
ALK positive Lung Cancer Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan Objectives What is ALK translocation? What drugs are used in what sequence? How many times
More informationNew options for old and new targets in NSCLC Rosario García Campelo Medical Oncology Unit University Hospital A Coruña
New options for old and new targets in NSCLC Rosario García Campelo Medical Oncology Unit University Hospital A Coruña Phase II GOAL TRIAL DESIGN Key inclusion criteria Patients with locally advanced or
More informationRuolo emergente dell immunoterapia nello stadio III. Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy)
Ruolo emergente dell immunoterapia nello stadio III Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy) Disclosures Advisory Boards / Honoraria / Speakers fee / Consultant for: MSD,
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationTissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~
16 th Dec. 2016. ESMO Preceptorship Program Non-Small-Cell Lung Cancer @Singapore Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ Research Institute for Disease of
More information